Oha-Medsp. z o.o.
Research and experimental development in natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2017-06-09
Share capital
5,000.00 PLN
Registered address
ul. Wolność 2/5u-80, 01-018 Warszawa, Poland
Electronic delivery address
AE:PL-49828-74042-JGVAF-15
Financials
Revenue history (in k)
From the notes
| Foreign sales | 66.35% of revenue ($224,175) | |
| Contingent liabilities | $0 |
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 17 days for 2021).
- 202503/07/2026
- 202424/06/2025
- 202316/07/2024
- 202212/07/2023
- 202101/08/2022
- 202025/06/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Industry · Research and experimental development in natural sciences and engineering111 / 277
Top 40%
Results vs industry
Revenue
This companyUSD 337.90kMedianUSD 152.85kAverageUSD 4.86m
Net profit
This companyUSD 101.12kMedianUSD -228.23AverageUSD 317.06k
Operating costs
This companyUSD 229.63kMedianUSD 187.91kAverageUSD 4.67m
Assets
This companyUSD 238.91kMedianUSD 278.35kAverageUSD 8.47m
Industry
Authorized Representatives
Honorata Ewa Pojmańskaage 37 – President of the Management Board
Olga Teresa Witkowskaage 46 – Attorney-in-fact (sole)
Manner of representation
Each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 33 | $445.71 | 33% | |
Honorata Ewa Pojmańskaage 37 | 33 | $445.71 | 33% |
Olga Teresa Witkowskaage 46 | 34 | $459.21 | 34% |
Agnieszka Małgorzata Pojmańska and Honorata Ewa Pojmańska hold a combined 66% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-08-01.
30 1600 1462 1802 7091 3000 0001
31 1160 2202 0000 0003 5068 9487
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 7, 2025 | Aid for microenterprises in the form of public interventions concerning electricity, gas or heat supplies | $372$372 | E.ON Polska S.A. | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $33$33 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Lymelab Pharma sp. z o.o.sp. k. | $424,756.39 | lymelabpharma.com | ||
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | ||
| NanosanguisS.A. | $192,701.50 | nanosanguis.com | ||
| Codeit4us Rndsp. z o.o. | $152,435.96 | codeit4us.com | ||
| VB IdeaP.S.A. | $44,631.63 | vbidea.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com | ||
| Nanostalsp. z o.o. | $8,607.48 | nanostal.com | ||
| IncellvuS.A. | $6,985.93 | incellvu.pl | ||
| NanotheaS.A. | $115.78 | nanothea.com |
FAQ
The main business activity of Oha-Med focuses on research and experimental development in natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on June 9, 2017.
The headquarters is located at: ul. Wolność 2, 01-018 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $159,567, representing an increase of 19.9% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $11,341. For comparison, in 2023 the loss was $56,648, meaning the company reduced its loss by 81.0%.
The largest operating cost category falls under employee remuneration. This category amounted to $79,260 in 2024, representing 47% of all operating expenses.
Last updated: 2026-07-06